CVRX INC (CVRX)
US1266381052 - Common Stock
We assign a fundamental rating of 2 out of 10 to CVRX. CVRX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. CVRX may be in some trouble as it scores bad on both profitability and health. CVRX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CVRX had negative earnings in the past year.
In the past year CVRX has reported a negative cash flow from operations.
In the past 5 years CVRX always reported negative net income.
CVRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -45.80%, CVRX is doing worse than 64.52% of the companies in the same industry.
CVRX has a Return On Equity of -89.71%. This is in the lower half of the industry: CVRX underperforms 62.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.8% | ||
| ROE | -89.71% | ||
| ROIC | N/A |
ROA(3y)-32.39%
ROA(5y)-33.93%
ROE(3y)-40.56%
ROE(5y)-357.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVRX's Gross Margin of 84.16% is amongst the best of the industry. CVRX outperforms 95.16% of its industry peers.
In the last couple of years the Gross Margin of CVRX has grown nicely.
The Profit Margin and Operating Margin are not available for CVRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.34%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CVRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CVRX has more shares outstanding
CVRX has a worse debt/assets ratio than last year.
2.2 Solvency
CVRX has an Altman-Z score of -2.69. This is a bad value and indicates that CVRX is not financially healthy and even has some risk of bankruptcy.
CVRX has a Altman-Z score of -2.69. This is in the lower half of the industry: CVRX underperforms 65.05% of its industry peers.
CVRX has a Debt/Equity ratio of 0.76. This is a neutral value indicating CVRX is somewhat dependend on debt financing.
CVRX has a worse Debt to Equity ratio (0.76) than 72.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.76 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.69 |
ROIC/WACCN/A
WACC9.17%
2.3 Liquidity
CVRX has a Current Ratio of 11.32. This indicates that CVRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CVRX (11.32) is better than 94.62% of its industry peers.
CVRX has a Quick Ratio of 10.23. This indicates that CVRX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.23, CVRX belongs to the best of the industry, outperforming 94.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.32 | ||
| Quick Ratio | 10.23 |
3. Growth
3.1 Past
CVRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.71%.
The Revenue has grown by 34.36% in the past year. This is a very strong growth!
CVRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 86.58% yearly.
EPS 1Y (TTM)-31.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.56%
Revenue 1Y (TTM)34.36%
Revenue growth 3Y86.58%
Revenue growth 5YN/A
Sales Q2Q%27.23%
3.2 Future
CVRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.10% yearly.
The Revenue is expected to grow by 25.85% on average over the next years. This is a very strong growth
EPS Next Y-32.5%
EPS Next 2Y-3.03%
EPS Next 3Y4.93%
EPS Next 5Y10.1%
Revenue Next Year29.71%
Revenue Next 2Y28.05%
Revenue Next 3Y27.44%
Revenue Next 5Y25.85%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CVRX. In the last year negative earnings were reported.
Also next year CVRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.03%
EPS Next 3Y4.93%
5. Dividend
5.1 Amount
CVRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CVRX INC
NASDAQ:CVRX (1/6/2025, 8:00:01 PM)
After market: 13.47 0 (0%)13.47
-0.17 (-1.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners69.7%
Inst Owner Change0%
Ins Owners4.9%
Ins Owner Change1.72%
Market Cap326.78M
Analysts78.46
Price Target18.53 (37.56%)
Short Float %8.93%
Short Ratio6.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.97%
Min EPS beat(2)-19.26%
Max EPS beat(2)-16.68%
EPS beat(4)1
Avg EPS beat(4)-25.91%
Min EPS beat(4)-88.53%
Max EPS beat(4)20.82%
EPS beat(8)5
Avg EPS beat(8)-7%
EPS beat(12)8
Avg EPS beat(12)-4.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-1.79%
Max Revenue beat(2)-0.73%
Revenue beat(4)0
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-7.46%
Max Revenue beat(4)-0.55%
Revenue beat(8)4
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.89%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.1%
PT rev (3m)31.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.57%
EPS NY rev (1m)2.11%
EPS NY rev (3m)1.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.92 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.01 | ||
| P/tB | 5.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS1.95
BVpS2.69
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.8% | ||
| ROE | -89.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.16% | ||
| FCFM | N/A |
ROA(3y)-32.39%
ROA(5y)-33.93%
ROE(3y)-40.56%
ROE(5y)-357.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.34%
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.76 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 258.29% | ||
| Cap/Sales | 3.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.32 | ||
| Quick Ratio | 10.23 | ||
| Altman-Z | -2.69 |
F-Score3
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)325.21%
Cap/Depr(5y)309.29%
Cap/Sales(3y)4.54%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.56%
EPS Next Y-32.5%
EPS Next 2Y-3.03%
EPS Next 3Y4.93%
EPS Next 5Y10.1%
Revenue 1Y (TTM)34.36%
Revenue growth 3Y86.58%
Revenue growth 5YN/A
Sales Q2Q%27.23%
Revenue Next Year29.71%
Revenue Next 2Y28.05%
Revenue Next 3Y27.44%
Revenue Next 5Y25.85%
EBIT growth 1Y-31.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.95%
EBIT Next 3Y-2.24%
EBIT Next 5YN/A
FCF growth 1Y-1.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.33%
OCF growth 3YN/A
OCF growth 5YN/A